Veracyte, the cancer diagnostics company, has acquired Convergent Genomics, a South San Francisco startup that developed a urine-based genomic test for bladder cancer, in a deal valued at up to $180 million. The acquisition was reported on September 21, 2026.
Veracyte is paying $150 million in cash upfront and up to $30 million in additional cash tied to milestones in securing reimbursement for Convergent's UroAmp platform.
Convergent's technology will be added to Veracyte's bladder cancer portfolio alongside its Decipher Bladder tissue test and TrueMRD blood-based test. Veracyte did not say what will happen to Convergent's laboratory or staff.
What Convergent Genomics built
Convergent was founded in 2015 in partnership with Oregon Health & Science University and the Illumina Accelerator. It operates a clinical laboratory in South San Francisco and runs research with more than 30 sites worldwide.
Its UroAmp platform analyses urinary tumour DNA, or utDNA. Non-muscle invasive bladder cancer usually stays within the bladder, so only small amounts of tumour DNA reach the bloodstream, which limits blood tests. Urine, by contrast, is in direct contact with the bladder lining and can carry tumour genetic material.
UroAmp has been clinically validated in non-muscle invasive bladder cancer, including for monitoring how patients respond to therapy and for surveillance after treatment. It is supported by nine peer-reviewed publications and more than 40 posters and abstracts. In the RUMBLE study published in The Journal of Urology, patients who looked clinically clear after initial BCG immunotherapy but tested positive for utDNA had a 12-month recurrence-free survival rate of 25%, against 91% for those who tested negative.
“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”
Why Veracyte is buying
About 85,000 people are diagnosed with bladder cancer in the US each year, according to Veracyte, around 65,000 of them with non-muscle invasive disease. Of roughly 750,000 Americans living with bladder cancer, about 600,000 have the non-muscle invasive form.
Veracyte said combining urine, tissue and blood tests would give doctors complementary information across the course of the disease. Its first planned product based on UroAmp is meant to show whether patients who have finished BCG induction therapy are likely to benefit from maintenance treatment. Veracyte expects to launch that test commercially in late 2028, depending on reimbursement timelines, and plans to study further uses in monitoring and surveillance.
How the test will be used
Veracyte's first UroAmp product is meant to identify whether patients who have completed induction therapy with Bacillus Calmette-Guerin (BCG) are likely to benefit from maintenance treatment. That is the setting studied in RUMBLE, where a positive utDNA result after induction was linked to much higher odds of recurrence within a year.
Veracyte also plans to study UroAmp for monitoring patients during maintenance therapy delivered into the bladder and for surveillance after treatment intended to cure the cancer. Used with Decipher Bladder, which analyses tumour tissue, and TrueMRD, which looks for residual disease in blood, the company wants to cover the full course of the disease with three types of sample.
The founders and the funding
Convergent has not disclosed much about its venture funding. Its UroAmp research was supported by a Small Business Innovation Research grant from the National Cancer Institute. The company is led by chief executive Brian Slingerland.
"We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer," Slingerland said.
What the price says
The structure of the deal, with $30 million held back for reimbursement milestones, shows how much the value of a diagnostic test depends on whether insurers will pay for it. Veracyte is betting that UroAmp can win that coverage in bladder cancer, as it plans for its first UroAmp-based test.
Of the maximum $180 million, $150 million is paid upfront in cash, so most of the value is not contingent. The remaining $30 million depends on progress with reimbursement for UroAmp, and Veracyte did not set out a timetable for those payments. The RUMBLE results it cites came from a multicentre prospective study.
